Regístrese gratis y obtenga acceso ilimitado a nuestra extensa biblioteca de elearning
Gane puntos CME y realice un seguimiento de su actividad de aprendizaje con cientos de horas de educación médica continua.
Updated Guidelines on the Management of Prostate Cancer in Older Patients
0 CME Points

Público destinatarios

This module is for medical practitioners who wish to gain knowledge on updated SIOG guidelines for the management of prostate cancer in older patients.

Objetivos educativos

By the end of this module, you should be able to:

  • Characterise the health status of elderly patients with prostate cancer.
  • Know what prostate cancer treatments are available for elderly patients.
  • Understand and apply treatment decisions to elderly prostate cancer patients.

Requisitos del sistema

This module requires the learner to have a good, stable internet connection and can run on Internet Explorer 7 and above, Mozilla Firefox, Google Chrome and Opera on either Windows or MacOS. Flash Add-on is also required to run this module.

If you are viewing this module on an iPad (through a browser), please download the free Articulate Mobile Player beforehand. Other tablet devices may not be compatible - please check for Flash compatibility.

If you are experiencing technical difficulties, please contact and we will get back to you as soon as possible.

Política de divulgación

ecancer and Prof Jean-Pierre Droz, MD, Professor of Medical Oncology, Department of Medical Oncology, Centre Léon-Bérard, Lyon, France (RPPS: 10003064887, declared in the Cayenne Hospital French Guiana) have no actual or potential conflict of interest whatsoever which impinges on the making, peer reviewing and dissemination of this e-learning module which was made possible through an unrestricted educational grant from Sanofi Oncology.

For a copy of the Transparency data of the French Government Health Ministry for Jean-Pierre Droz, please click here.


Production of this module was funded by the International Society of Geriatric Oncology (SIOG) and by an unrestricted grant from Sanofi.